MarketPulse

dose escalation

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sapu Nano / Oncotelic Therapeutics

Sapu Nano Advances mTOR Therapy With First Patient in Everolimus IV Trial

Sapu Nano dosed first patient in Phase 1b trial of intravenous everolimus formulation for advanced cancers including breast cancer and renal cell carcinoma.
OTLCbreast cancerneuroendocrine tumors
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Eupraxia Pharmaceuticals Advances EP-104GI Data Ahead of Key Medical Conference

Eupraxia Pharmaceuticals to present Phase 1b/2 clinical data for EP-104GI at Digestive Disease Week 2026, showcasing efficacy in eosinophilic esophagitis treatment.
EPRXEP-104GIeosinophilic esophagitis
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Radiopharm Theranostics Advances RAD202 Trial to Higher Dose Cohort

Radiopharm Theranostics advances RAD202 radiopharmaceutical trial to higher dose cohort following positive safety review, remaining on track for 2026 Phase 1 completion.
RADXPhase 1 clinical trialoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Radiopharm Theranostics

Radiopharm Theranostics Advances Novel Prostate Cancer Therapy With First Patient Dosed

Radiopharm Theranostics doses first patient in Phase 1 trial of RAD 402, a targeted radioimmune therapy for advanced prostate cancer, with data expected H2 2026.
RADXmonoclonal antibodyPhase 1 clinical trial